S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall

ADC Therapeutics Stock Price, News & Analysis (NYSE:ADCT)

$1.03
-0.08 (-7.21%)
(As of 12/5/2023 ET)
Compare
Today's Range
$0.97
$1.09
50-Day Range
$0.47
$1.13
52-Week Range
$0.36
$5.75
Volume
411,786 shs
Average Volume
478,315 shs
Market Capitalization
$79.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75

ADC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
256.0% Upside
$3.67 Price Target
Short Interest
Bearish
6.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.38) to ($1.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

514th out of 948 stocks

Pharmaceutical Preparations Industry

224th out of 421 stocks


ADCT stock logo

About ADC Therapeutics Stock (NYSE:ADCT)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Stock Price History

ADCT Stock News Headlines

ADC Therapeutics: Navigating A Swirling Drain
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Analyst Expectations for ADC Therapeutics's Future
Sobi to present new data at ASH 2023 Annual Meeting
TD Cowen Downgrades Adc Therapeutics (ADCT)
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Q3 2023 ADC Therapeutics SA Earnings Call
What Wall Street expects from ADC Therapeutics's earnings
ADC Therapeutics SA ADCT
Puma Biotech (PBYI) Tops Q3 Earnings Estimates
See More Headlines
Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
317
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.67
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+458.3%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
6 Analysts

Profitability

Net Income
$-155,800,000.00
Net Margins
-145.64%
Pretax Margin
-148.08%

Debt

Sales & Book Value

Annual Sales
$122.57 million
Book Value
$1.16 per share

Miscellaneous

Free Float
49,619,000
Market Cap
$79.11 million
Optionable
Not Optionable
Beta
1.24
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Ameet Mallik M.B.A. (Age 50)
    M.S., CEO & Director
    Comp: $819.74k
  • Mr. Jose I. Carmona M.B.A. (Age 51)
    Chief Financial Officer
  • Dr. Patrick van Berkel Ph.D. (Age 55)
    Chief Scientific Officer
  • Dr. Michael Mulkerrin Ph.D. (Age 68)
    Chief Technical Operations Officer
  • Amanda Hamilton
    Investor Relations Officer
  • Ms. Susan Romanus (Age 58)
    Chief Compliance & Quality Officer
  • Mr. Peter J. Graham Esq. (Age 56)
    Chief Legal Officer
  • Ms. Kimberly Pope (Age 56)
    Senior VP & Chief People Officer
  • Ms. Kristen Harrington-Smith (Age 50)
    Chief Commercial Officer
  • Dr. Mohamed Zaki M.D. (Age 58)
    Ph.D., Chief Medical Officer














ADCT Stock Analysis - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings
or view top-rated stocks.

What is ADC Therapeutics' stock price target for 2024?

6 analysts have issued 12 month price targets for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 256.0% from the stock's current price.
View analysts price targets for ADCT
or view top-rated stocks among Wall Street analysts.

How have ADCT shares performed in 2023?

ADC Therapeutics' stock was trading at $3.84 at the beginning of 2023. Since then, ADCT shares have decreased by 73.2% and is now trading at $1.03.
View the best growth stocks for 2023 here
.

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,620,000 shares, a decline of 8.8% from the October 31st total of 3,970,000 shares. Based on an average trading volume of 297,800 shares, the short-interest ratio is presently 12.2 days. Approximately 6.8% of the shares of the stock are short sold.
View ADC Therapeutics' Short Interest
.

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ADCT earnings forecast
.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.03. The business earned $14.49 million during the quarter, compared to the consensus estimate of $14.57 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 1,121.94% and a negative net margin of 145.64%.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (18.46%), Affinity Asset Advisors LLC (1.43%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:ADCT) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -